Cost effectiveness of fondaparinux in non-ST-elevation acute coronary syndrome

PharmacoEconomics

Volumn 27, Issue 7, 2009, Pages 585-595

  Latour Perez, Jaime ^a   De Miguel Balsa, Eva ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CORONARY ARTERY BYPASS GRAFT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HEART MUSCLE REVASCULARIZATION; HOSPITAL COST; HUMAN; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNIVARIATE ANALYSIS;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; DECISION SUPPORT TECHNIQUES; ELECTROCARDIOGRAPHY; HUMANS; MARKOV CHAINS; POLYSACCHARIDES;

EID: 68949146765     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11310120-000000000-00000     Document Type: Article

References (49)

1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction. Circulation 2007; 116: e148-304
2. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660
3. Blankenship JC. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J 1999; 138 (4 Pt 2): s287-96
4. Stone GW, Bertrand ME, Moses JW, et al. Routine up-stream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 2007; 297: 591-602
5. Latour-Pérez J, De-Miguel-Balsa E, Alcalá-López A, et al. Effectiveness and safety of triple antiaggregation in patients undergoing coronary intervention. Med Intensiva 2007; 31: 220-230
6. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782
7. Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 28: 1936-1945
8. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-1476
9. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419-458
10. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-338
11. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-842
12. Bosch X, Marrugat J. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction. Cochrane Database Syst Rev 2001; (4): CD002130
13. Budaj A, Yusuf S, Mehta SR, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002; 106: 1622-1626
14. Glaser R, Glick HA, Herrmann HC, et al. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis. J Am Coll Cardiol 2006; 47: 529-537
15. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000; 101: 366-371
16. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533
17. Robinson M, Palmer S, Sculpher M, et al. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling. Health Technol Assess 2005; 9: iii-xi, 1-158
18. Scirica BM, Cannon CP, Antman EM, et al. Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. Am J Cardiol 2002; 90: 303-305
19. Steinhubl SR, Berger PB, Mann 3rd JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420
20. Latour-Perez J, De-Miguel-Balsa E, Betegon L, et al. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis. Value Health 2008; 11 (5): 853-861
21. Instituto Nacional de Estad?́stica. Tablas de Mortalidad de la Población de España 1992-2005 [online]. Available from URL: http://www.ine.es/jaxi/menu.do?type=pcaxis&path=%2Ft20%2Fp319a&file= inebase&L=0 [Accessed 2008 Mar 31]
22. Beck JR, Pauker SG, Gottlieb JE, et al. A convenient approximation of life expectancy (the 'DEALE'): II. Use in medical decision-making. Am J Med 1982; 73: 889-897
23. Sox HC, Blatt MA, Higgins MC, et al. Medical decision making: measuring the outcome of care. Toronto (ON): Butterworth-Heinemann, 1988: 167-200
24. Badia X, Bueno H, Gonzalez Jr J, et al. Short-and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain. Rev Esp Cardiol 2005; 58: 1385-1395
25. Cequier A, Moris C, Badia X, et al. Cost minimization analysis of bivalirudin versus heparin plus planned abcix-imab in patients undergoing percutaneous coronary intervention. Rev Esp Econ Salud 2006; 5: 168-176
26. Consejo General de Colegios de Farmacéuticos. BOT [online]. Available from URL: http://pfarmals.portalfarma. com/default.asp. [Accessed 2008 Mar 31]
27. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49: 1362-1368
28. Mathis AS, Gugger JJ. Percutaneous coronary intervention-related bleeding risk factors in current practice. Ann Pharmacother 2005; 39: 1627-1633
29. Oliva G, Espallargues M, Pons JM. Antiproliferative drugeluting stents: systematic review of the benefits and estimate of economic impact. Rev Esp Cardiol 2004; 57: 617-628
30. Russell S, Antonanzas F, Mainar V. Economic impact of the taxus coronary stent: implications for the Spanish healthcare system. Rev Esp Cardiol 2006; 59: 889-896
31. Instituto Nacional de Estad?́stica. Indice de precios al consumo. INE [online]. Available from URL: http://www.ine. es/daco/ipc.htm [Accessed 2007 Feb 25]
32. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
33. Haddix AC, Teutsch SM, Corso PS. Prevention effective-ness. 2nd ed. New York: Oxford University Press, 2003
34. Eckman MH, Levine HJ, Salem DN, et al. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. Chest 1998; 114 (5 Suppl.): 699S-714S
35. Kalish SC, Gurwitz JH, Krumholz HM, et al. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med 1995; 10: 321-330
36. Kuntz KM, Tsevat J, Goldman L, et al. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 1996; 94: 957-965
37. Allen LA, O'Donnell CJ, Camargo CA, et al. Comparison of long-term mortality across the spectrum of acute coronary syndromes. Am Heart J 2006; 151: 1065-1071
38. Herlitz J, Karlson BW, Sjölin M, et al. Ten year mortality in subsets of patients with an acute coronary syndrome. Heart 2001; 86: 391-396
39. Lim MJ, Spencer FA, Gore JM, et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. Eur Heart J 2005; 26: 1063-1069
40. Mueller C, Neumann FJ, Perruchoud AP, et al. Renal function and long term mortality after unstable angina/ non-ST segment elevation myocardial infarction treated very early and predominantly with percutaneous coronary intervention. Heart 2004; 90: 902-907
41. Hunink M, Glasziou P. Decision making in health and medicine: integrating evidence and values. Cambridge: Cambridge University Press, 2001
42. Dinh P, Zhou XH. Nonparametric statistical methods for cost-effectiveness analyses. Biometrics 2006; 62: 576-588
43. Sacristan JA, Oliva J, Del LJ, et al. What is an efficient health technology in Spain? Gac Sanit 2002; 16: 334-343
44. Lyseng-Williamson KA, Plosker GL. Clopidogrel: a phar-macoeconomic review of its use in patients with non-ST elevation acute coronary syndromes. Pharmacoeconomics 2006; 24 (7): 709-726
45. Plosker GL, Lyseng-Williamson KA. Clopidogrel: a review of its use in the prevention of thrombosis. Drugs 2007; 67 (4): 613-646
46. Plosker GL, Ibbotson T. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes. Pharmacoeconomics 2003; 21 (12): 885-912
47. Sculpher MJ, Lozano-Ortega G, Sambrook J, et al. Fonda-parinux versus enoxaparinin non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. Am Heart J 2009; 157: 845-852
48. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J2003; 24:1815-1823
49. Segev A, Strauss BH, Tan M, et al. Constance predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J 2005; 150:690-694